References
- Demol P, Schmitz H D, Weihrauch T R, Kuhlmann J. Prevention of the acetylsalicylic acid-induced changes of the gastric potential difference by the new synthetic prostaglandin E1 analogue, rioprostil. Arzneim Forsch Drug Res 1986; 36: 1406–1408
- Demol P, Wingender W, Weihrauch T R, Graefe K H. Inhibition of gastric secretion in man by rioprostil, a new synthetic methyl prostaglandin E1. Arzneim Forsch/Drug Res 1985; 35: 861–863
- Dammann H G, Walter Th A, Müller P, Simon B. Night-time rioprostil versus ranitidine in duodenal ulcer healing. Lancet 1986; ii: 335–336
- Howden C W, Jones D B, Burget D W, Kerr G D, Hunt R H. Acid suppression in healing duodenal ulcer: how much is enough?. Gut 1986; 27: A611
- Charlet N, Gallo-Torres H E, Bounaxmeaux Y, Wills R J. Prostaglandins and the protection of the gas-troduodenal mucosa in humans: a critical review. J Clin Pharmacol 1985; 25: 564–582
- Hawkey C J, Walt R P. Prostaglandins for peptic ulcer: a promise unfulfilled. Lancet 1986; ii: 1084–1086
- Howden C W. Rioprostil and duodenal ulcer. Lancet 1986; 2: 686
- Boyd E JS, Wilson J A, Wormsley K G. Smoking impairs therapeutic gastric inhibition. Lancet 1983; i: 95–97
- Bauerfeind P, Cilluffo T, Fimmel C J, et al. Does smoking interfere with the effect of histamine H2-receptor antagonists on intragastric acidity in man?. Gut 1987; 28: 549–556